Allergan completes acquisition of AqueSys Allergan plc.

‘The treatment of glaucoma is progressively shifting to dropless therapies given the challenges of patient compliance. The XEN45 device provides a minimally invasive approach to lowering IOP for doctors and their patients seeking new ways to deal with glaucoma that go beyond conventional eye drop remedies.’ Related StoriesQ BioMed indications definitive license contract with Mannin ResearchAllergan enters into agreement to acquire Aquesys and its XEN45 programQuethera receives seed purchase funding to develop gene therapy for glaucomaXEN45 provides received a CE mark in europe where it really is indicated for the reduced amount of intraocular pressure in patients with primary open angle glaucoma where previous procedures have got failed. The CE mark allows treatment in conjunction with a cataract process or as a standalone treatment.ACP urges Congress to attain agreement on comprehensive wellness reform legislation The American University of Physicians today urged Congressional leaders to ‘reach agreement on a legislative pathway to provide affordable care to all or any Americans and ensure that they have access to primary care physicians and other specialties facing shortages.’ In a letter to essential legislators, ACP President Joseph W. Stubbs, MD, FACP, said: ‘We agree with the President that Congress must full the task of enacting comprehensive health reform legislation consistent with the above priorities.

Copyright blindserver.com 2018